Market TodayThemes and Stocks SummaryThematic Stock SearchCrypto SummaryFAQAbout
MYGN - Myriad Genetics, Inc.
0.57(2.88%)8:59:59 PM 1/27/2023
Myriad Genetics, Inc. is an American molecular diagnostic company based in Salt Lake City, Utah, United States. Myriad employs a number of proprietary technologies that permit doctors and patients to understand the genetic basis of human disease and the role that genes play in the onset, progression and treatment of disease. This information is used to guide the development of new molecular diagnostic products that assess an individual's risk for developing disease later in life , identify a patient's likelihood of responding to a particular drug therapy , assess a patient's risk of disease progression and disease recurrence , and measure disease activity. Following the discovery by Mary-Claire King that a gene on chromosome 17 is associated with an increased risk of breast cancer, Myriad attempted to patent this gene. These patents were the subject of scrutiny after Myriad became involved in a lawsuit over its patenting practices, which led to the landmark Supreme Court decision Association for Molecular Pathology v. Myriad Genetics, Inc. which ruled these patents illegal.
Stock Chart

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 


Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.


  • Volatility is at a recent 2 week high. A high volatility of stock movement indicates uncertainty.
  • A moving average of Short volume ratio is at a recent 2 week high. A high short volume ratio indicate selling presures.
  • MACD is crossing MACD signal line at 0.4. MACD crossing signal line is bullish signal.
Stock Statistics
PE Ratio-20.4
PEG Ratio21.2
P/S (ttm)3.6
Earning Growth (QoQ)
Revenue Growth (QoQ)
Short %10%
Held by Institutions %100%
1 Day Vol Adjusted Return-1.0
1 Month Vol Adjusted Return8.0
3 Month Vol Adjusted Return0.3
6 Month Vol Adjusted Return-6.3
20 Days SMA Price ZScore0.9
50 Days SMA Price ZScore0.8
12 -26 Days PPO4.7
1 Month Average Short Volume Ratio52.4
1 Day Volume Change ZScore-0.5
1 Month Daily Vol3.3
Related Topics

Stock news

    Raymond James Upgrades Natera & Myriad Genetics, While Downgrading This Stock

    Raymond James upgraded Natera Inc (NASDAQ: NTRA) to Outperform from Market Perform and a price target of $58 on a catalyst-rich setup for 2023 across segments, but most interestingly, in the molecular residual disease arena. The analyst expects additional coverage and potential guideline inclusion, at least for colorectal cancer, with women's health having its catalysts. The analyst also upgraded Myriad Genetics Inc (NASDAQ: MYGN) to Outperform from Market Perform and a price target of $25. Raym

    Myriad Genetics (MYGN) Ailed by Mounting Costs, FX Headwind

    Myriad Genetics' (MYGN) significant gross margin contraction and operating loss as a result of mounting cost pressure are concerning.

    Myriad Genetics Applauds New Guidelines Recommending Screening for Chromosomal Abnormalities

    Myriad Genetics continues to advance non-invasive prenatal screening with Prequel® and the forthcoming FirstGene™ test using AMPLIFY™ technology SALT LAKE CITY, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced its support for a recent guideline update by the American College of Medical Genetics and Genomics (ACMG), reaffirming the clinical value of non-invasive prenatal screening (NIPS) for a range of chr

    Myriad Genetics to Present at 41st Annual J.P. Morgan Healthcare Conference

    SALT LAKE CITY, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Paul J. Diaz, president and chief executive officer, and Dale Muzzey, chief scientific officer, will present at the 41st Annual J.P. Morgan (JPM) Healthcare Conference on Monday, Jan. 9, 2023 at 4:30 p.m. PST/7:30 p.m. EST. The presentation will be available through a live webcast on the Myriad Genetics Investor Relations website. An archive

    Myriad Genetics Hires Five Senior Leaders to Advance Commercial Growth Plans

    New leaders to elevate product portfolio, customer-centric commercial capabilities, and sales and marketing execution SALT LAKE CITY, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the addition of five senior executives to help further strengthen the company’s product roadmap and improve commercial execution. Marc Leighton recently joined Myriad as Senior Vice President (SVP) for Product Management. Lei

    Further weakness as Myriad Genetics (NASDAQ:MYGN) drops 5.5% this week, taking five-year losses to 51%

    Statistically speaking, long term investing is a profitable endeavour. But along the way some stocks are going to...

    Myriad Genetics Patient Outcomes Study Shows RiskScore Leads to More Accurate Breast Cancer Risk Prediction than Standard-of-Care Risk Model

    Myriad’s MyRisk™ Hereditary Cancer test with RiskScore® provides a personalized breast cancer risk assessment for women of all ancestriesSALT LAKE CITY, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today presented results from a longitudinal study validating RiskScore as a well-calibrated and more accurate predictor of breast cancer risk than a standard-of-care risk assessment alone. The data was shared in a spotlight

    Halozyme Therapeutics (HALO) Up 16.2% Since Last Earnings Report: Can It Continue?

    Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium Showcasing Advancements in Breast Cancer Risk Assessment and Treatment

    Spotlight discussion highlights how combined risk score may lead to improved breast cancer prevention and screening strategies. SALT LAKE CITY, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN) a leader in genetic testing and precision medicine, today announced multiple presentations of new data at the 2022 San Antonio Breast Cancer Symposium (SABCS), including a spotlight discussion on breast cancer risk prediction. “Genetic testing is an essential tool across the continuu

    GeneSight Mental Health Monitor Reveals Gap on the Front Line of Mental Health Care

    Survey finds primary care providers wish patients would raise mental health concerns so they can provide better overall careSALT LAKE CITY, Nov. 17, 2022 (GLOBE NEWSWIRE) -- More than 83% of primary care providers (PCPs) wish more of their patients would talk to them about mental health issues and concerns so they can provide better overall care, according to the latest GeneSight® Mental Health Monitor, a nationwide survey from Myriad Genetics, Inc. (NASDAQ: MYGN). Yet, results of the Spring 202